Back to search results

Losartan for Preventing Scarring After ACL Surgery

This study is investigating whether taking losartan, a blood pressure medication with anti-scarring properties, can reduce the risk of abnormal scar tissue (arthrofibrosis) forming in the knee after anterior cruciate ligament (ACL) repair surgery. You may be able to join if you are 18 or older, have reached skeletal maturity, and are having a primary ACL reconstruction, possibly with other common knee procedures. The study aims to see if losartan improves your knee's range of motion 12 months after surgery. The current recruitment status is unclear, but the study plans to enroll 144 participants.

Study design
This interventional study will involve 144 participants. It will compare losartan capsules to identical-looking placebo capsules (inactive medicine).
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your knee's range of motion will be measured 12 months after surgery to see the long-term effects.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07135687

Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction

Not Yet Recruiting
PHASE4Ages 18+Interventional
Rush University Medical Center
~144 participants
Updated 2025-12-15 on ClinicalTrials.gov
What's tested:LosartanPlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Range of Motion
Measured over 12 months

Conditions

ACL Injury
ACL Reconstruction
Scar Formation

Explore related trials

Injury of anterior cruciate ligament

NCT07135687

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Rush University Medical Center

    Chicago, Illinoisstudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jorge Chahla, MD, PhD · PRINCIPAL_INVESTIGATOR · Rush University Medical Center
  • Andrew Bi, MD · PRINCIPAL_INVESTIGATOR · Rush University Medical Center

Who to contact

Jorge Chahla, MD, PhD
[email protected]
(312) 432-2452
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Must be undergoing a primary ACLR with or without the following:
Chondroplasty
Synovectomy
Loose body removal
Removal of hardware
Meniscal surgery (excluding meniscal allograft transplantation/MAT)
Lateral extra-articular tenodesis
Must have skeletal maturity in the distal femur and proximal tibial physes
Must be age 18 years or older at time of enrollment

Exclusion

\<18 years at time of enrollment
No diagnosis of ACL tear
ACL repairs
Revision ACL reconstructions
Open distal femur or proximal tibia physes
Major concomitant procedures (such as osteotomy, MAT, or cartilage restoration surgery)
History of prior proximal or distal femur fracture (including those receiving nonoperative treatment)
History of prior ipsilateral femur or tibia osteomyelitis
Medical history
History of hypotensive disease, including postural orthostatic hypotension syndrome (POTS), autonomic dysreflexia, or Shy-Drager syndrome (aka multiple system atrophy), baseline hypotension \<90 systolic or \<60 diastolic mmHg.
History of significant hepatic disease (liver transplantation, cirrhosis of any cause, or any liver disease with Child-Pugh classification B or C) due to hepatic metabolism of ARBs.
Chronic kidney disease
Rheumatologic disorders on immunologic medications
Current medications including diuretics (i.e. furosemide), lithium, and spironolactone
Current hypertension with prescription of an ARB or ACE-I
Allergy to losartan
Current pregnancy or breastfeeding

What this trial measures

  • Range of Motion12 months

    Range of motion measured from baseline to 12 months